The big challenges of the future of global pig production are food safety, antibiotic use, animal welfare and the environmental impact, all aspects defined in sustainable production. The industry has very high production standards however consumers often don't value this.
Ingelheim, Germany, 13 December 2016 – Having reached the milestone of 1 billion doses sold since launch, yet another vaccine of Boehringer Ingelheim Animal Health crosses a significant threshold making it one of the leading vaccines for the control of Mycoplasma hyopneumoniae globally(1).
During the last fifty years or so, disease control in the pork industry has evolved mainly relying on antimicrobials, vaccines, elimination (depopulation, repopulation, eradication, modified early weaning), and/or regional control depending on the disease.
Pig production has responded to the challenge of increased global demand for pork by a process of consolidation and increased size to capture benefits of economies of scale. Over the last 25 years the swine industry has evolved in order to increase production performance, health and animal wellbeing towards age segregated or multiple site production models. In general, it can be stated that the changes in production systems have produced a positive effect in the health status of pigs by improving the way we raise pigs today.
CHINA - Ingelvac CircoFLEX from Boehringer Ingelheim Vetmedica is the first vaccine to be approved in China against Porcine Circovirus Disease (PCVD). Boehringer Ingelheim Vedmedica GmbH has been granted market authorisation for a vaccine for the control of Porcine Circovirus Disease (PCVD) by the Chinese regulatory authorities.
Reinstate balance by:
Reducing the risk of infection caused by stress such as regrouping/moving
Securing colostrum-intake
Applying alternatives to antibiotics: PRRS-vaccination of suckling pigs protects their immune cells
→ The reduction of bacterial load brings balance and better health
Get the latest news on Swine Health Subscribe to our newsletter